Panretin(alitretinoin)
Panretin (alitretinoin) is a small molecule pharmaceutical. Alitretinoin was first approved as Panretin on 1999-02-02. It is used to treat kaposi sarcoma and skin diseases in the USA. It has been approved in Europe to treat kaposi sarcoma. The pharmaceutical is active against retinoic acid receptor beta, vitamin K epoxide reductase complex subunit 1, retinoic acid receptor gamma, and retinoic acid receptor alpha. In addition, it is known to target retinoic acid receptor RXR-beta, retinoic acid receptor RXR-gamma, and retinoic acid receptor RXR-alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Panretin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alitretinoin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PANRETIN | Concordia Laboratories | N-020886 RX | 1999-02-02 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| panretin | New Drug Application | 2021-08-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| kaposi sarcoma | — | D012514 | C46 |
| skin diseases | — | D012871 | L00-L99 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D11: Other dermatological preparations in atc
— D11A: Other dermatological preparations in atc
— D11AH: Agents for dermatitis, excluding corticosteroids
— D11AH04: Alitretinoin
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XF: Retinoids for cancer treatment
— L01XF02: Alitretinoin
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Eczema | D004485 | HP_0000964 | L30.9 | — | 1 | 4 | — | — | 5 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | 1 | 2 | — | — | 3 |
| Hand dermatoses | D006229 | — | — | — | — | 3 | — | — | 3 |
| Male breast neoplasms | D018567 | — | — | — | — | 1 | — | — | 1 |
| Ichthyosis | D007057 | — | E50.8 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatic insufficiency | D048550 | — | — | 1 | 1 | — | — | 1 | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
| Kaposi sarcoma | D012514 | — | C46 | — | 1 | — | — | 1 | 2 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 1 |
| Lichen planus | D008010 | — | L43 | — | 1 | — | — | — | 1 |
| Cutaneous lupus erythematosus | D008178 | EFO_0003834 | L93.1 | — | 1 | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alitretinoin |
| INN | alitretinoin |
| Description | 9-cis-retinoic acid is a retinoic acid in which the exocyclic double bonds have 7E,9Z,11E,13E geometry. It has a role as an antineoplastic agent, a retinoid X receptor agonist, a metabolite and a keratolytic drug. It is a conjugate acid of a 9-cis-retinoate. |
| Classification | Small molecule |
| Drug class | retinol derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1 |
Identifiers
| PDB | — |
| CAS-ID | 5300-03-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL705 |
| ChEBI ID | 50648 |
| PubChem CID | 449171 |
| DrugBank | DB00523 |
| UNII ID | 1UA8E65KDZ (ChemIDplus, GSRS) |
Target
Agency Approved
RARB
RARB
Organism
Homo sapiens
Gene name
RARB
Gene synonyms
HAP, NR1B2
NCBI Gene ID
Protein name
retinoic acid receptor beta
Protein synonyms
HBV-activated protein, hepatitis B virus activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-beta, RAR-epsilon, retinoic acid receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Rarb (218772)
retinoic acid receptor beta (P22605)
Alternate
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 760 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
69 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use